文献速递淋巴瘤

复发或难治性侵袭性B细胞淋巴瘤患者接受epcoritamab或glofitamab治疗的真实世界结局

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.
PubMed 文献 · Blood · 2025-01-01

该研究从21家美国机构收集了2023年1月1日至2024年10月15日期间接受商业化epcoritamab或glofitamab治疗的245例复发或难治性弥漫性大B细胞淋巴瘤患者,其中156例接受epcoritamab、89例接受glofitamab。epcoritamab和glofitamab的总体缓解率分别为51%(完全缓解23%)和53%(完全缓解30%),中位无进展生存期为2.6个月,中位总生存期为7.8个月。基线CD20不可检测与更差的无进展生存和总生存相关。

要点

  • 在245例真实世界复发或难治性弥漫性大B细胞淋巴瘤患者中,epcoritamab和glofitamab的总体缓解率分别为51%和53%。
  • 中位无进展生存期为2.6个月,中位总生存期为7.8个月,6个月无进展生存率为36%,6个月总生存率为60%。
  • 试验不合格和基线CD20不可检测均与更短的无进展生存和总生存相关。

核心结论

  • 该分析显示复发或难治性弥漫性大B细胞淋巴瘤患者对CD3/CD20双特异性抗体的总体缓解率与关键试验相当,但无进展生存和总生存更低。
  • 基线CD20不可检测水平与不良结局相关,结果证明双特异性抗体在复发或难治性弥漫性大B细胞淋巴瘤中的活性,并强调靶抗原表达的重要性。

研究设计与样本

  • 从21家美国机构收集2023年1月1日至2024年10月15日期间接受商业化epcoritamab或glofitamab治疗的复发或难治性弥漫性大B细胞淋巴瘤患者。
  • 共纳入245例患者,其中156例接受epcoritamab,89例接受glofitamab;113例对一线治疗难治,40例有MYC和BCL2和/或BCL6重排,147例既往接受过嵌合抗原受体T细胞治疗,174例不符合注册试验入组条件。

主要发现

  • epcoritamab的总体缓解率为51%(完全缓解23%),glofitamab的总体缓解率为53%(完全缓解30%)。
  • 中位无进展生存期为2.6个月(95%置信区间[CI],2.0-3.8个月),中位总生存期为7.8个月(95% CI,6.2-11.0个月)。
  • 6个月无进展生存率为36%(95% CI,30-44),6个月总生存率为60%(95% CI,54-67)。
  • 试验不合格和基线CD20不可检测均预示更短的无进展生存和总生存。
  • 在17例有配对活检的个体中,15例(88.2%)在双特异性抗体治疗后丢失CD20表达,中位至进展时间为3.7个月。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Epcoritamab and glofitamab are CD20-directed bispecific antibodies (BsAbs) approved in the United States for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Limited data exist for patients treated outside of trials. Patients with R/R DLBCL receiving commercial epcoritamab or glofitamab between 1 January 2023 and 15 October 2024 were collected from 21 United States institutions. Among 245 patients, 156 received epcoritamab and 89 received glofitamab, 113 were refractory to front-line therapy, 40 had MYC and BCL2 and/or BCL6 rearrangements, 147 received prior chimeric antigen receptor T-cell therapy, and 174 patients would have been ineligible for registrational trials. The overall response rate (ORR) for epcoritamab and glofitamab was 51% (23% complete response, [CR]) and 53% (30% CR), respectively. Median progression-free survival (PFS) was 2.6 months (95% confidence interval [CI], 2.0-3.8 months), and median overall survival (OS) was 7.8 months (95% CI, 6.2-11.0 months). The 6-month PFS was 36% (95% CI, 30-44) and the 6-month OS was 60% (95% CI, 54-67). Both trial ineligibility and undetectable CD20 pre-BsAbs portended shorter PFS and OS. Of 17 individuals with paired biopsies, 15 (88.2%) lost CD20 expression after BsAbs with a median time to progression of 3.7 months. This analysis including patients with R/R DLBCL shows the ORR to CD3/CD20 BsAbs was comparable to pivotal trials, although PFS and OS were lower. Baseline undetectable levels of CD20 were associated with poor outcomes. These results demonstrate the activity of BsAbs in R/R DLBCL, and underscore the importance of target antigen expression.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Brooks TR, Zabor EC, Bedelu YB, et al. Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. 2025. PMID: 40663785. doi:10.1182/blood.2025029117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。